Global Cancer Immunotherapy Market: Overview
Due to the attendance of a pool of large and small companies, the global cancer immunotherapy market makes for an uneven competitive market. Healthcare suppliers are aiming at enhancing treatments and lowering in the reappearance of cancer after chemotherapy. On the other hand, adverse effects related to the drugs and high cost is impacting the growth of the global cancer immunotherapy market.
|Historic Years||2016 - 2020|
|Forecast Years||2021 - 2028|
|Segments Covered||By Product Type, By Application, and By End Use|
|Forecast Units||Value (USD Billion), and Volume (Units)|
|Quantitative Units||Revenue in USD million/billion and CAGR from 2021 to 2028|
|Regions Covered||North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World|
|Countries Covered||U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others|
|Number of Companies Covered||10 companies with scope for including additional 15 companies upon request|
|Report Coverage||Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.|
|Customization Scope||Avail customized purchase options to meet your exact research needs.|
Global Cancer Immunotherapy Market: Growth Factors
Growing acceptance of immunotherapy over conventional and traditional therapeutics, prevalence of cancer, rising demand for cancer monoclonal antibodies, growth of bioinformatics equipments that provide improved drug development alternatives, rising popularity of assistance programs for patient, and huge profile of pledging pipeline are a handful of prominent points anticipated to boost the global cancer immunotherapy market in the forecast period.
In converse, copyright expiry of some of the top drugs in the sector, poor infrastructure of screens and diagnosis in a lot of emerging nations, danger of side effects, very high price of development of innovative drugs, and severe laws from different governments before the drug is given the endorsement are most of the hurdles hindering the growth of the global cancer immunotherapy market.
Nonetheless, the merchants operating in the global cancer immunotherapy market stand to get new chances from tactical alliances by the merchants to branch out geologically, rising consciousness related to the occurrence of cancer amongst urban inhabitants on account of radical infiltration in the past decade by social media, appearance of biosimilars, as well as combination and targeted therapies.
Global Cancer Immunotherapy Market: Segmentation
On the basis of a therapy type, the global cancer immunotherapy market is segmented into monoclonal antibodies, immune checkpoint inhibitors, PD-1/PD-L1, CTLA-4, immune system modulators, cancer vaccines, and others. The segment of monoclonal antibodies offers the utmost demand, although inhibitors of the immune checkpoint are expected for an enhanced development rate. On the basis of therapeutic area, the global cancer immunotherapy market has been divided into lung cancer, breast cancer, melanoma, prostate cancer, blood cancer, colorectal cancer, and others. Based on the end user, the global cancer immunotherapy market is classified into hospitals, ambulatory surgical centers (ASCs), cancer research centers, and specialty clinics.
Global Cancer Immunotherapy Market: Regional Analysis
North America holds the biggest income share for the global cancer immunotherapy market. Increasing ease of authorization to modern therapeutics, increasing the incidence of the disease, and growing geriatric population, is boosting the global cancer immunotherapy market in the area. However, factors such as hurdles in clinical trials along with quickly changing policies of reimbursement and higher costs are hindering global cancer immunotherapy market growth in North America.
The Asia Pacific is anticipated to witness the fastest growth of the global cancer immunotherapy market. Increasing incidence of the disease and in return, the mounting rate of mortality is driving requirement for the global cancer immunotherapy market in the area. In addition to this, attendance of market players with huge investments in the global cancer immunotherapy market is driving the growth in the Asia Pacific.
Global Cancer Immunotherapy Market: Competitive Players
The global cancer immunotherapy market is extremely spirited. Main companies comprise AstraZeneca, Amgen, Inc., Bayer AG, F. Hoffmann La Roche Ltd., Eli Lilly and Company, Bristol-Myers Squibb Company, Novartis AG, Merck and Co., Inc., and Pfizer, Inc.
Global Cancer Immunotherapy Market: Regional Segment Analysis
What Reports Provides
Request the coronavirus impact analysis across industries and markets